GlassScriptPhysician profile
David A Wiersema
NPI 1851322549
$17,019.15
in general payments reported to CMS, 2019-2025
35 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what 92% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $564 · 2021: $509 · 2022: $5,359 · 2023: $1,914 · 2024: $6,432 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,788 · Food and Beverage: $3,158 · Travel and Lodging: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,787.50 |
| Food and Beverage | $3,158.48 |
| Travel and Lodging | $1,188.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,753.88 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Neurocrine Biosciences, INC. | $928.46 | 2019-2025 | Ingrezza |
| Allergan, INC. | $559.86 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $226.69 | 2023-2024 | Quviviq |
| Eisai INC. | $184.04 | 2020-2021 | |
| Amgen INC. | $182.31 | 2019-2023 | Evenity, Prolia |
| Avanir Pharmaceuticals, INC. | $138.67 | 2019-2021 | |
| Radius Health, INC. | $121.21 | 2019-2024 | Tymlos |
| Abbott Laboratories | $68.11 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $65.22 | 2019-2025 | |
| Exact Sciences Corporation | $64.81 | 2024-2025 | Cologuard Collection Kit |
| Ucb, INC. | $56.47 | 2025 | Nayzilam, Briviact |
| Otsuka America Pharmaceutical, INC. | $53.15 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $51.33 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $48.23 | 2022-2025 | Xeomin |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $47.79 | 2019-2020 | |
| Lundbeck LLC | $47.33 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $44.66 | 2021-2024 | Dysport |
| Lilly USA, LLC | $42.00 | 2019-2020 | |
| Antares Pharma, INC. | $40.43 | 2024-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $35.04 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Saol Therapeutics INC. | $33.00 | 2022 | |
| Electronic Waveform Lab, INC. | $31.47 | 2019 | |
| Glaxosmithkline, LLC. | $20.88 | 2024 | Trelegy Ellipta |
| Novo Nordisk INC | $19.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.27 | 2025 | Xifaxan |
| Alvogen INC | $17.93 | 2023 | Teriparatide |
| Takeda Pharmaceuticals U.S.A., INC. | $17.85 | 2025 | Trintellix |
| Tolmar, INC. | $16.70 | 2024 | |
| Collegium Pharmaceutical, INC. | $16.67 | 2025 | Belbuca |
| Kowa Pharmaceuticals America, INC. | $15.18 | 2025 | Zoryve |
| Medtronic USA, INC. | $14.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.79 | 2019 | |
| Redhill Biopharma INC. | $12.46 | 2020 | |
| Merz North America, INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wiersema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.